High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude

Bibhuti B. Das, Robert R. Wolfe, Kak Chen Chan, Gary L. Larsen, John T. Reeves, Dunbar Ivy

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Pulmonary hypertension has not been described as a predisposing risk factor for high-altitude pulmonary edema (HAPE) in children. Previous studies have shown an association of HAPE with abnormally increased pulmonary vasoreactivity to hypoxia but generally normal pulmonary artery pressure (PAP) after recovery. Objective: To describe HAPE of relatively rapid onset and its management in a series of children residing at moderate to high altitudes, all of whom had underlying pulmonary hypertension. Methods and Results: From 1997 to 2003, 30 children came to our center with high-altitude illness. Of these, 10 children (aged 4-18 years; male-female ratio, 8:2) living at moderate to high altitudes (1610-3050 m) underwent cardiac catheterization after recovery from HAPE, and all were found to have chronic pulmonary hypertension (mean PAP, 38 ± 9 mm Hg; pulmonary vascular resistance, 8.6 ± 2.8 U × m2). Increases in PAP and pulmonary vascular resistance to hypoxia (16% oxygen) suggest that these children have a reactive pulmonary pressor response and hence are susceptible to HAPE. Six of the 10 patients had predisposing cardiopulmonary abnormalities, and 5 of these 6 patients did not receive a diagnosis prior to the onset of HAPE. Long-term treatment with calcium channel blockers, bosentan, sildenafil citrate, and/or oxygen lowered PAP, improved symptoms, and prevented the recurrence of HAPE. Conclusion: Children living at altitude who develop HAPE should undergo screening for diagnosis of underlying cardiopulmonary abnormalities including pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)1170-1176
Number of pages7
JournalArchives of Pediatrics and Adolescent Medicine
Volume158
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Pulmonary Edema
Pulmonary Hypertension
Pulmonary Artery
Pressure
Vascular Resistance
Oxygen
Lung
Calcium Channel Blockers
Cardiac Catheterization
Causality
Recurrence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. / Das, Bibhuti B.; Wolfe, Robert R.; Chan, Kak Chen; Larsen, Gary L.; Reeves, John T.; Ivy, Dunbar.

In: Archives of Pediatrics and Adolescent Medicine, Vol. 158, No. 12, 12.2004, p. 1170-1176.

Research output: Contribution to journalArticle

Das, Bibhuti B. ; Wolfe, Robert R. ; Chan, Kak Chen ; Larsen, Gary L. ; Reeves, John T. ; Ivy, Dunbar. / High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. In: Archives of Pediatrics and Adolescent Medicine. 2004 ; Vol. 158, No. 12. pp. 1170-1176.
@article{323ad288e01545cfab6e75fcd35d9980,
title = "High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude",
abstract = "Background: Pulmonary hypertension has not been described as a predisposing risk factor for high-altitude pulmonary edema (HAPE) in children. Previous studies have shown an association of HAPE with abnormally increased pulmonary vasoreactivity to hypoxia but generally normal pulmonary artery pressure (PAP) after recovery. Objective: To describe HAPE of relatively rapid onset and its management in a series of children residing at moderate to high altitudes, all of whom had underlying pulmonary hypertension. Methods and Results: From 1997 to 2003, 30 children came to our center with high-altitude illness. Of these, 10 children (aged 4-18 years; male-female ratio, 8:2) living at moderate to high altitudes (1610-3050 m) underwent cardiac catheterization after recovery from HAPE, and all were found to have chronic pulmonary hypertension (mean PAP, 38 ± 9 mm Hg; pulmonary vascular resistance, 8.6 ± 2.8 U × m2). Increases in PAP and pulmonary vascular resistance to hypoxia (16{\%} oxygen) suggest that these children have a reactive pulmonary pressor response and hence are susceptible to HAPE. Six of the 10 patients had predisposing cardiopulmonary abnormalities, and 5 of these 6 patients did not receive a diagnosis prior to the onset of HAPE. Long-term treatment with calcium channel blockers, bosentan, sildenafil citrate, and/or oxygen lowered PAP, improved symptoms, and prevented the recurrence of HAPE. Conclusion: Children living at altitude who develop HAPE should undergo screening for diagnosis of underlying cardiopulmonary abnormalities including pulmonary hypertension.",
author = "Das, {Bibhuti B.} and Wolfe, {Robert R.} and Chan, {Kak Chen} and Larsen, {Gary L.} and Reeves, {John T.} and Dunbar Ivy",
year = "2004",
month = "12",
doi = "10.1001/archpedi.158.12.1170",
language = "English (US)",
volume = "158",
pages = "1170--1176",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude

AU - Das, Bibhuti B.

AU - Wolfe, Robert R.

AU - Chan, Kak Chen

AU - Larsen, Gary L.

AU - Reeves, John T.

AU - Ivy, Dunbar

PY - 2004/12

Y1 - 2004/12

N2 - Background: Pulmonary hypertension has not been described as a predisposing risk factor for high-altitude pulmonary edema (HAPE) in children. Previous studies have shown an association of HAPE with abnormally increased pulmonary vasoreactivity to hypoxia but generally normal pulmonary artery pressure (PAP) after recovery. Objective: To describe HAPE of relatively rapid onset and its management in a series of children residing at moderate to high altitudes, all of whom had underlying pulmonary hypertension. Methods and Results: From 1997 to 2003, 30 children came to our center with high-altitude illness. Of these, 10 children (aged 4-18 years; male-female ratio, 8:2) living at moderate to high altitudes (1610-3050 m) underwent cardiac catheterization after recovery from HAPE, and all were found to have chronic pulmonary hypertension (mean PAP, 38 ± 9 mm Hg; pulmonary vascular resistance, 8.6 ± 2.8 U × m2). Increases in PAP and pulmonary vascular resistance to hypoxia (16% oxygen) suggest that these children have a reactive pulmonary pressor response and hence are susceptible to HAPE. Six of the 10 patients had predisposing cardiopulmonary abnormalities, and 5 of these 6 patients did not receive a diagnosis prior to the onset of HAPE. Long-term treatment with calcium channel blockers, bosentan, sildenafil citrate, and/or oxygen lowered PAP, improved symptoms, and prevented the recurrence of HAPE. Conclusion: Children living at altitude who develop HAPE should undergo screening for diagnosis of underlying cardiopulmonary abnormalities including pulmonary hypertension.

AB - Background: Pulmonary hypertension has not been described as a predisposing risk factor for high-altitude pulmonary edema (HAPE) in children. Previous studies have shown an association of HAPE with abnormally increased pulmonary vasoreactivity to hypoxia but generally normal pulmonary artery pressure (PAP) after recovery. Objective: To describe HAPE of relatively rapid onset and its management in a series of children residing at moderate to high altitudes, all of whom had underlying pulmonary hypertension. Methods and Results: From 1997 to 2003, 30 children came to our center with high-altitude illness. Of these, 10 children (aged 4-18 years; male-female ratio, 8:2) living at moderate to high altitudes (1610-3050 m) underwent cardiac catheterization after recovery from HAPE, and all were found to have chronic pulmonary hypertension (mean PAP, 38 ± 9 mm Hg; pulmonary vascular resistance, 8.6 ± 2.8 U × m2). Increases in PAP and pulmonary vascular resistance to hypoxia (16% oxygen) suggest that these children have a reactive pulmonary pressor response and hence are susceptible to HAPE. Six of the 10 patients had predisposing cardiopulmonary abnormalities, and 5 of these 6 patients did not receive a diagnosis prior to the onset of HAPE. Long-term treatment with calcium channel blockers, bosentan, sildenafil citrate, and/or oxygen lowered PAP, improved symptoms, and prevented the recurrence of HAPE. Conclusion: Children living at altitude who develop HAPE should undergo screening for diagnosis of underlying cardiopulmonary abnormalities including pulmonary hypertension.

UR - http://www.scopus.com/inward/record.url?scp=9644262373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644262373&partnerID=8YFLogxK

U2 - 10.1001/archpedi.158.12.1170

DO - 10.1001/archpedi.158.12.1170

M3 - Article

C2 - 15583103

AN - SCOPUS:9644262373

VL - 158

SP - 1170

EP - 1176

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 12

ER -